Researchers at Mayo Clinic report in JAMA Neurology that a blood measure of phosphorylated Tau 217 (p-tau217), a biomarker linked to Alzheimer's disease, may help estimate a cognitively healthy person's risk of developing mild cognitive impairment or dementia over the next five or 10 years. The approach pairs the p-tau217 level with age, sex and genetic risk. In the study, higher p-tau217 levels and older age were both associated with greater risk.
The team's aim was a personalized probability rather than a simple positive or negative result. Alicia Algeciras-Schimnich, the study's first author, said that a risk figure is more meaningful to a patient than whether amyloid pathology is present or absent. The work extends earlier Mayo Clinic research that used PET brain scans to measure amyloid and predict later impairment. A blood test is less invasive and potentially easier to scale.
The analysis drew on 1,644 cognitively unimpaired participants in the Mayo Clinic Study of Aging and 534 participants in the Alzheimer's Disease Neuroimaging Initiative, all aged 60 to 90, who had p-tau217 measurements, genetic testing and repeated cognitive assessments. The Mayo Clinic data were used to estimate five- and 10-year risks, and the Alzheimer's Disease Neuroimaging Initiative data were used to confirm the link between higher p-tau217 and greater cognitive decline.
The differences in the example figures are notable. A 75-year-old woman without the APOE e4 variant had an estimated five-year MCI risk of 5% at a relatively low p-tau217 level and 16% at a higher level, with her 10-year risk rising from 12% to 35%. Age also mattered considerably: at the same high p-tau217 level, five-year MCI risk ranged from 6% at age 65 to 37% at age 85.
Ronald Petersen, director of the Mayo Clinic Study of Aging, noted that these numbers could become important for treatment decisions if preventive therapies prove effective. Two prevention trials, AHEAD 3-45 and TRAILBLAZER-ALZ 3, are testing whether amyloid-targeting drugs can delay decline before symptoms appear, and both used blood biomarkers to identify participants. The researchers caution that the risk estimates were developed in the Mayo Clinic Study of Aging and need testing in more diverse populations and with other p-tau217 tests. They also state that Alzheimer's biomarker testing is not currently recommended for people without cognitive symptoms.